On 11 October Russia-24 aired a Technopark episode dedicated to
GEROPHARM — the first company on the Russian market which developed its
own technology and established an industrial production of genetically
engineered human insulin on the basis of a full cycle — starting from
the substance up to the ready dosage form.
In the current difficult foreign policy situation the ability of the
industry to provide its own domestic market with essential drugs,
including insulin, is of a great concern. Until recently, up to 70% of
the pharmaceutical products were presented with imported drugs. The
domestic sector has examples of successful new enterprises, which have
already created modern technological platforms, introduced the know-how,
and produce modern medicines in accordance with the world standards.
One such company is GEROPHARM-Bio, part of the GEROPHARM Group of
Companies. Today insulin has become a consumer product rather than a
category of medicines. Every year the need of the country for insulin
increases by 20%. That is why the development of the Russian full cycle
production of such a socially significant medicine is a priority and the
key to drug safety.
The following people took part in the program: Petr Rodionov, Head of
GEROPHARM, Group of Companies, Gleb Feldman, Head of Biotechnology
Department of GEROPHARM, Group of Companies, Sergey Tsyb, Deputy
Minister of Industry and Trade of the Russian Federation, Elena
Maksimkina, Director of the Department for Pharmacological Support and
Regulation of the Circulation of Medical Supplies, Ministry of
Healthcare of Russia, and Alexander Potapov, Deputy CEO, Executive
Director and Board Member of the RVC.